mRNA therapeutics in 2026: overview
mRNA therapeutics give cells instructions to produce a therapeutic protein or trigger an immune response. The platform can be adapted to different targets without changing its basic production logic, supporting vaccines as well as cancer immunotherapy and protein replacement. The central challenge is delivering intact RNA to the right cells while controlling its expression and the immune response it provokes.
Research is pushing beyond infectious-disease vaccines toward cancer immunotherapy and organ-directed delivery. In September 2026, Sun Yat Sen University researchers reported spleen-selective mRNA expression using ionizable lipidoid linkers. In October 2026, Queen Mary University of London scientists described using viral protein NoV B2 to help self-amplifying vaccines overcome cellular defenses. Delivery, inflammatory effects, durability and product quality remain key technical hurdles.
- 1Beyond vaccines: Cancer immunotherapy and protein replacement are extending mRNA research into treatments where target selection and control of expression are central.
- 2Delivery is pivotal: Lipid nanoparticles remain a major delivery approach, while organ-selective expression and non-lipid carriers address limits in where and how mRNA reaches cells.
- 3saRNA gains ground: Self-amplifying RNA activity rose 16% against the previous 12-month period, alongside work to address its interaction with cellular defenses.
Top organizations working on mRNA therapeutics
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to mRNA therapeutics. Showing 7 of 3,000 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Moderna Therapeutics
Corporate · United States |
Conventional linear mRNA | PUB 225 · NEWS 1,680 | -20% | Moderna develops mRNA vaccines and therapeutics, applying its platform across infectious diseases, cancer, and protein-replacement indications. |
| 2 | 
Pfizer
Corporate · United States |
Conventional linear mRNA | PAT 6 · PUB 82 NEWS 1,248 |
-49% | Pfizer develops mRNA vaccines with BioNTech, including COVID-19 vaccines and combination respiratory-vaccine candidates. |
| 3 | 
University of Pennsylvania
Research · United States |
Lipid nanoparticle delivery | PUB 326 · NEWS 805 | -34% | Penn researchers are investigating mRNA-LNP vaccines for cancer prevention, including a prophylactic approach targeting breast cancer. |
| 4 | 
U.S. National Institutes of Health
Research · United Kingdom |
General | PUB 221 · NEWS 823 | -36% | Recently, the NIH awarded a Pioneer grant to support Nicoli’s work developing a new kind of mRNA therapy. |
| 5 | 
GSK GlaxoSmithKline
Corporate · United Kingdom |
Conventional linear mRNA | PAT 7 · PUB 35 NEWS 793 |
-63% | Recently, GSK prepared a Phase 3 study of its experimental mRNA seasonal influenza vaccine in adults. |
| 6 | 
Sanofi S.A.
Corporate · France |
Conventional linear mRNA | PAT 27 · PUB 54 NEWS 642 |
-51% | Sanofi has pursued mRNA vaccines and therapeutics, including through its acquired mRNA platform and vaccine-development programs. |
| 7 | Conventional linear mRNA | PAT 31 · PUB 41 NEWS 551 |
-42% | Recently, BioNTech discontinued a Phase 2 trial of its personalized mRNA cancer vaccine autogene cevumeran after a futility review. | |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 12 total
HDT Bio CorporationUnited StatesHDT Bio develops self-replicating RNA vaccines; preclinical work has explored thermostable lyophilized formulations and candidates for infectious diseases.- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 2,753 total
- University of PennsylvaniaUnited StatesPenn researchers are investigating mRNA-LNP vaccines for cancer prevention, including a prophylactic approach targeting breast cancer.
- U.S. National Institutes of HealthUnited KingdomRecently, the NIH awarded a Pioneer grant to support Nicoli’s work developing a new kind of mRNA therapy.
Fudan UniversityChinaRecently, Fudan researchers reported tumor-targeted delivery of circular RNA encoding an IL-15 prodrug and studied LNP designs for vaccine delivery.- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where mRNA therapeutics innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 3,000 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Conventional linear mRNA | Linear mRNA provides transient protein expression and a well-established design path, but can require repeat dosing and careful control of innate immune activation. | 989 |
University of Pennsylvania, Curevac Inc., Pfizer |
| Self-amplifying RNA | Self-amplifying RNA copies itself inside cells to support protein production from less starting material, but its replication machinery can intensify innate immune responses. | 961 |
Insightace Analytic, Edgar, Dunn & Company, Biomedical Research |
| Circular RNA | Circular RNA can support prolonged translation, but its manufacture, purification and quality control present distinct challenges. | 2,197 |
Edgar, Dunn & Company, Insightace Analytic, Precision Medicine |
| Lipid nanoparticle delivery | Lipid nanoparticles protect RNA and enable cellular uptake, but distribution beyond the liver and inflammatory effects can limit therapeutic use. | 6,287 |
Moderna Therapeutics, University of Pennsylvania, U.S. Food and Drug Administration |
| Non-lipid delivery | Non-lipid carriers offer alternatives for targeting and formulation, but must demonstrate reliable RNA protection, delivery and expression. | 1,600 |
University of Texas M. D. Anderson Cancer Center, Insightace Analytic, U.S. Food and Drug Administration |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
FACTS reports $509,308,509 in grants across 427 grants since 2020. The funding-round aggregate is $59,341,344,690 across 31 rounds, but listed examples include unrelated projects, so it should not be read as mRNA-specific investment.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Oct 2026saRNA vaccines hold great promise but are hindered by an inherent flaw which undermines their effectiveness. Scientists at Queen Mary University of London discovered that adding a viral protein called NoV B2 helps…Scientific Inquirer
- Aug 2026Member-only story RNA as the Programmable Language of Medicine Just a few days ago, a piece of news once again placed three letters at the heart of one of the most fascinating scientific stories of our time: RNA.…Technology on Medium
- Aug 2026Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and…GlobeNewswire - Industry News on Industrials
- Aug 2026Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally…English – The Conversation
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about mRNA therapeutics
What companies are working on mRNA therapeutics?
Moderna Therapeutics, Pfizer, BioNTech AG, Sanofi S.A., GSK GlaxoSmithKline, Merck And Co., and Novartis are among the companies active in mRNA therapeutics. Their work includes vaccines and cancer programs; Moderna also applies its platform to protein replacement. Novartis has licensed an mRNA-encoded T-cell engager from Abogen, while Merck and Moderna have reported progress on a personalized cancer vaccine.
Which mRNA therapeutics startups are promising in 2026?
HDT Bio Corporation is the startup named in FACTS, with a focus on self-replicating RNA vaccines. Its work includes preclinical exploration of thermostable lyophilized formulations and infectious-disease candidates. The available facts do not provide enough comparative evidence to rank it against other startups or assess which candidate is most likely to succeed.
Which universities and research centers lead mRNA therapeutics research?
University of Pennsylvania, Fudan University and Sun Yat Sen University are among the prominent research organizations in FACTS. Penn researchers are investigating mRNA-LNP vaccines for cancer prevention. Fudan researchers have reported tumor-targeted circular RNA delivery, while Sun Yat Sen University researchers have studied HPV16 mRNA vaccines and spleen-selective expression.
How much funding has mRNA therapeutics received?
FACTS records $509,308,509 in grants across 427 grants since 2020. It also lists $59,341,344,690 across 31 funding rounds, but the examples include projects that are not clearly related to mRNA therapeutics. Treat that round total cautiously rather than as a verified measure of investment in this field.
Who holds the most mRNA therapeutics patents?
Curevac Inc. holds the largest listed patent count, with 46, followed by Modernatx Inc. with 44 and Regeneron Pharmaceuticals Inc with 29. BioNTech AG has 27 listed patents, and Sanofi S.A. has 25. These counts identify patent holders in FACTS; they do not by themselves indicate patent quality or commercial value.
Is mRNA therapeutics patent activity growing?
No: patent growth was -50.9% over the last 12 months compared with the previous 12 months. FACTS lists 2,721 patents in the 24-month window. This overall decline sits alongside different patterns among approaches: self-amplifying RNA activity grew, while conventional linear mRNA and circular RNA activity declined.
What are the latest developments in mRNA therapeutics?
Recent work includes spleen-selective mRNA expression using ionizable lipidoid linkers, reported by Sun Yat Sen University researchers in August 2026. In October 2026, Queen Mary University of London scientists described using viral protein NoV B2 to help self-amplifying vaccines overcome cellular defenses. Other active research areas include personalized cancer vaccines and pulmonary delivery.
What are the main approaches in mRNA therapeutics, and how do they differ?
The main approaches are conventional linear mRNA, self-amplifying RNA, circular RNA, lipid nanoparticle delivery and non-lipid delivery. Linear mRNA produces transient expression; self-amplifying RNA adds intracellular replication; circular RNA may support prolonged translation. Lipid and non-lipid delivery approaches differ in carrier design, with both seeking to protect RNA and direct it to target cells.
What are the applications of mRNA therapeutics?
FACTS identifies immunomodulation (13,535 documents), regenerative medicine (5,225), cancer immunotherapy (4,532), infectious disease vaccines (4,265) and protein replacement (2,696). These applications use mRNA to stimulate or shape immune activity, support tissue repair, target tumors, prevent infection or prompt production of a needed protein.